Skip to main content Accessibility help
  • Print publication year: 2010
  • Online publication date: August 2010

11 - Physical health issues


American Academy of Pediatrics Committee on Drugs (2000). Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics, 105, 880–7.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.
APA (2001). The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association, 2nd edition. Washington, DC: American Psychiatric Press.
APA (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). TheAmerican Journal of Psychiatry, 159, 1–50.
Barnett, A.H., Mackin, P., Chaudhry, I., et al. (2007). Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology (Oxford, England), 21, 357–73.
Ben-Menachem, E. (2007). Weight issues for people with epilepsy. Epilepsia, 48, 42–5.
Bjorntorp, P. (1996). The regulation of adipose tissue distribution in humans. International Journal of Obesity and Related Metabolic Disorders, 20, 291–302.
Bowden, C.L., Calabrese, J.R., Ketter, T.A., et al. (2006). Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar 1 disorder. The American Journal of Psychiatry, 163, 1199–201.
Bowden, C.L., Calabrese, J.R., McElroy, S.L., et al.; Divalproex Maintenance Study Group (2000). A randomised, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar disorder. Archives of General Psychiatry, 57, 481–9.
Calabrese, J.R., Bowden, C.L., Sachs, G.S., et al.; Lamictal Study Group (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar 1 depression. The Journal of Clinical Psychiatry, 60, 79–88.
Caligiuri, M.R., Jeste, D.V., Lacro, J.P. (2000). Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs & Aging, 17, 363–84.
Cassidy, F., Ritchie, J.C., Carroll, B.J. (1998). Plasma dexamethasone concentration and cortisol response during manic episodes. Biological Psychiatry, 43, 747–54.
Chaudron, L.H. & Jefferson, J.W. (2000). Mood stabilizers during breastfeeding: a review. The Journal of Clinical Psychiatry, 61, 79–90.
Chrousos, G.P. & Gold, P.W. (1992). The concepts of stress and stress system disorders. Overview of physical and behavioural homeostasis. JAMA, 267, 1244–52.
Cohen, L.S., Friedman, J.M., Jefferson, J.W., et al. (1994). A re-evaluation of risk of in utero exposure to lithium. JAMA, 271, 146–50.
Cohen, L.S., Sichel, D.A., Robertson, L.M., et al. (1995). Postpartum prophylaxis for women with bipolar disorder. The American Journal of Psychiatry, 152, 1641–5.
Colton, C.W. & Manderscheid, R.W. (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease, 3, A42.
Correll, C.U. & Schenk, E.M. (2008). Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry, 21, 151–6.
De Backer, G., Ambrosioni, E., Borch-Johnsen, K., et al. (2003). European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal, 24, 1601–10.
Dentino, A.N., Pieper, C.F., Rao, M.K., et al. (1999). Association of interleukin-6 and other biologic variables with depression in older people living in the community. Journal of the American Geriatrics Society, 47, 6–11.
Expert group (2004). ‘Schizophrenia and Diabetes 2003’ Expert Consensus Meeting, Dublin, 3–4 October 2003: consensus summary. The British Journal of Psychiatry Supplement, 47, S112–14.
Fagiolini, A., Frank, E., Scott, J.A., et al. (2005). Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorder, 7, 424–30.
Fagiolini, A., Chengappa, K.N., Soreca, I., et al. (2008). Bipolar disorder and metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs, 22, 655–69.
Gitlin, M.J. (1993). Lithium-induced renal insufficiency. Journal of Clinical Psychopharmacology, 13, 276–9.
GlaxoSmithKline (2009). The Lamotrigine Pregnancy Registry. Interim report 1 September 1992 through 31 March 2009. Issued July 2009. [accessed 10 January 2010].
Graham, I., Atar, D., sBorch- Johnsen, K., et al. (2007). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European Heart Journal, 28, 2375–414.
Greenhill, L.L., Vitiello, B., Riddle, M.A., et al. (2003). Review of safety assessment methods used in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 627–33.
Guberman, A.H., Besag, F.M., Brodie, M.J., et al. (1999). Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia, 40, 985–91.
Gupta, A., Lawrence, A.T., Krishnan, K., et al. (2007). Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. American Heart Journal, 153, 891–9.
Harris, E.C. & Barraclough, B. (1998). Excess mortality of mental disorder. The British Journal of Psychiatry, 173, 11–53.
Hennekens, C.H. (1998). Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation, 97, 1095–102.
Hippisley-Cox, J., Parker, C., Coupland, C., Vinogradova, Y. (2007). Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart, 93, 1256–62.
Holmang, A. & Bjorntorp, P. (1992). The effects of cortisol on insulin sensitivity in muscle. Acta Physiologica Scandinavica, 144, 425–31.
Holmes, L.B., Harvey, E.A., Coull, B.A., et al. (2001). The teratogenicity of anticonvulsant drugs. New England Journal of Medicine, 344, 1132–8.
Jarema, M. (2007). Atypical antipsychotics in the treatment of mood disorders. Current Opinion in Psychiatry, 20, 23–9.
Joffe, H., Cohen, L.S., Suppes, T., et al. (2006). Valproate is associated with new-onset oligomenorrhea with hyperandrogenism in women with bipolar disorder. Biological Psychiatry, 59, 1078–86.
Johnston, A.M. & Eagles, J.M. (1999). Lithium-associated clinical hypothyroidism: prevalence and risk factors. The British Journal of Psychiatry, 175, 336–9.
Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., et al. (2003). Developmental pharmacology – drug disposition, action, and therapy in infants and children. The New England Journal of Medicine, 349, 1157–67.
Lambert, T.J. & Chapman, L.H. (2004). Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. The Medical Journal of Australia, 181, 544–8.
Leipzig, R.M., Cumming, R.G., Tinetti, M.E. (1999). Drugs and falls in older people: a systematic review and meta-analysis, I: psychotropic drugs. Journal of the American Geriatrics Society, 47, 30–9.
Lepkifker, E., Sverflik, A., Iancu, I., et al. (2004). Renal insufficiency in long-term lithium treatment. The Journal of Clinical Psychiatry, 65, 850–6.
Li, T.Y., Rana, J.S., Manson, J.E., et al. (2006). Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation, 113, 499–506.
Llewellyn, A., Stowe, Z.N., Strader, J.R. (1998). The use of lithium and management of women with bipolar disorder during pregnancy and lactation. The Journal of Clinical Psychiatry, 59 (Suppl. 6), 57–64.
Markowitz, G.S., Radhakrishnan, J., Kambham, N., et al. (2000). Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. Journal of the American Society of Nephrology, 11, 1439–48.
National Collaborating Centre for Mental Health (2006). Bipolar Disorder: the Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. London: NICE. [accessed 3 January 2010].
NCEP ATP III (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report (2002). Circulation, 106, 3143–421.
Newcomer, J.W. & Hennekens, C.H. (2007). Severe mental illness and risk of cardiovascular disease. JAMA, 298, 1794–6.
Osby, U., Brandt, L., Correia, N., et al. (2001). Excess mortality in bipolar and unipolar disorder in Sweden. Archives of General Psychiatry, 58, 844–50.
Regenold, W.T., Thapar, R.K., Marano, C., et al. (2002). Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychiatric drug use. Journal of Affective Disorder, 70, 19–26.
Rosmond, R. & Bjorntorp, P. (1998). Blood pressure in relation to obesity, insulin and the hypothalamic-pituitary-adrenal axis in Swedish men. Journal of Hypertension, 16, 1721–6.
Sachs, G., Bowden, C., Calabrese, J.R., et al. (2006). Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar 1 disorder. Bipolar Disorders, 8, 175–81.
Scherk, H., Pajonk, F.G., Leucht, S. (2007). Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Archives of General Psychiatry, 64, 442–5.
Soreca, I., Mauri, M., Castrogiovanni, S., et al. (2007). Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment. Bipolar Disorders, 9, 784–8.
Szalat, A., Mazeh, H., Freund, H.R. (2009). Lithium-associated hyperparathyroidism: report of four cases and review of literature. European Journal of Endocrinology, 160, 317–23.
Tarsy, D. & Baldessarini, R.J. (2006). Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?Movement Disorders, 21, 589–98.
Taylor, V. & MacQueen, G. (2006). Associations between bipolar disorder and metabolic syndrome: a review. The Journal of Clinical Psychiatry, 67, 1034–41.
Van Gerpen, M.W., Johnson, J.E., Winstead, D.K. (1999). Mania in the geriatric patient population: a review of the literature. The American Journal of Geriatric Psychiatry, 7, 188–202.
Viguera, A.C., Nonacs, R., Cohen, L.S., et al. (2000). Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. The American Journal of Psychiatry, 157, 179–84.
Viguera, A.C., Whitfield, T., Baldessarini, R.J., et al. (2007). Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. The American Journal of Psychiatry, 164, 1817–24; quiz 1923.
Yonkers, K.A., Wisner, K.L., Stowe, Z., et al. (2004). Management of bipolar disorder during pregnancy and the postpartum period. The American Journal of Psychiatry, 161, 608–20.
Yoshida, K., Smith, B., Kumar, R. (1999). Psychotropic drugs in mothers’ milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding. Journal of Psychopharmacology(Oxford, England), 13, 64–80.
Zajecka, J.M., Weisler, R., Sachs, G., et al. (2002). A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. The Journal of Clinical Psychiatry, 63, 1148–55.
Zakrzewska, K.E., Cusin, I., Sainsbury, A., et al. (1997). Glucocorticoids as counter regulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes, 46, 717–19.